GlassScriptPhysician profile
Leah Lester
NPI 1154095321
$2,681.92
in general payments reported to CMS, 2019-2025
27 companies · $59.21 in 2025
The $59.21 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $1,112 · 2023: $856 · 2024: $542 · 2025: $59.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.99 | 2022-2025 | |
| Lilly USA, LLC | $319.27 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $258.96 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $188.08 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.09 | 2022-2024 | Trintellix |
| Medtronic, INC. | $167.30 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $135.04 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $129.03 | 2022 | |
| Sumitomo Pharma America, INC. | $115.51 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $93.94 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $81.54 | 2021-2024 | Airsupra, Breztri |
| Amgen INC. | $52.12 | 2022-2023 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $49.39 | 2022-2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $41.33 | 2022-2023 | Accrufer |
| Exact Sciences Corporation | $27.51 | 2023-2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.80 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $25.63 | 2022 | |
| Corcept Therapeutics | $25.50 | 2023 | Korlym |
| Sunovion Pharmaceuticals INC. | $24.64 | 2022 | |
| Cvrx, INC. | $24.03 | 2025 | Barostim Neo System |
| Biohaven Pharmaceutical Holding Company LTD. | $23.39 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.44 | 2023 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $18.62 | 2022 | |
| Smith+Nephew, INC. | $18.40 | 2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.27 | 2022 | |
| Currax Pharmaceuticals LLC | $14.04 | 2024 | Contrave, Onzetra Xsail |
| Almatica Pharma LLC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Lester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.